Alkermes’ Antipsychotic Clears US FDA Panel Amid Calls For Broader Professional Education Plan
Communication and education on samidorphan’s opioid antagonistic effects should focus on health care providers that prescribe opioids as well as psychiatrists that prescribe olanzapine, advisory committee says in endorsing the safety and efficacy of ALKS 3831.
You may also be interested in...
After Lybalvi’s Solid Early Launch, Alkermes Touts Neuropsychiatry Potential
Alkermes tells J.P. Morgan audience it hopes new combo Lybalvi and established Aristada will boost each other and the neuropsychiatric franchise. But the firm noted its addiction drug Vivitrol requires complicated commercial plan.
Keeping Track: US FDA Approval Binge Includes Brexafemme, Wegovy, Ryplazim, Truseltiq, Lybalvi, Tembexa
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Alkermes Expects Gradual Ramp-Up For Lybalvi Launch
Alkermes’ combo pill of olanzapine and samidorphan gets US FDA approval; company predicts $10m first-year sales as schizophrenia/bipolar patients cycle through treatment options, including generics.